CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
NCT03067155
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
1
Enrollment
OTHER
Sponsor class
Conditions
Hematological Malignancies
CMV Infection
Interventions
GENETIC:
CMV-specific T cells
DRUG:
Standard anti-viral therapy
Sponsor
University Hospital, Ghent